INITIAL RESULTS FROM UTERINE FIBROID EMBOLIZATION FOR SYMPTOMATIC LEIOMYOMATA

Objective: To assess the initial results of uterine artery embolization (UAE) for symptomatic leiomyomas. Material and Methods: This prospective cohort study was performed in the Radiology Department of Kuwait Teaching Hospital, from 1 August 2022 to 31st July 2023, on 204 consecutively registered patients. Patients 20 yrs and above with symptomatic leiomyomata were included in the study. No upper limit for uterus or fibroid volume was kept. Patients with gynaecological malignancy, undiagnosed pelvic mass, acute pelvic infection, pregnancy, menopause, contraindication to MRI and allergy to contrast agents were excluded from the study. Follow-up evaluation was performed 3 months after the procedure to assess volume reduction, infarction rates, and symptom improvement. Results: The ages of the patient were grouped in clusters of 10 yrs. 45.1% of the patients were found in 31-40 yrs age group. Majority of the fibroids were found in intramural location comprising 69.1%. 47.1% of the patients had single fibroid. Bleeding was resolved in 185 among 192 patients (96.3%) which means that only 7 patients were still having menorrhagia; bulk/pressure symptoms and pelvic pain was resolved in all of the patients. Conclusion: UAE is an effective, minimally invasive, uterus-preserving treatment for symptomatic fibroids, providing significant symptom relief and improved outcomes.